Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    22664749 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs Syndrome
Condition: Restless Legs Syndrome
Interventions: Drug: GEn (XP13512/GSK1838262);   Drug: Placebo

Indicates status has not been verified in more than two years